Integra LifeSciences Holdings Corporation (IART)
Valuation Overview•Is Integra LifeSciences Holdings Corporation Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Fragile underlying quality score of 26/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
IART struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company exhibits steady, low-single-digit revenue growth paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 5.8%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $391.9M | +1.5% | +1.6% | +3.6% | +6.4% | |
| EBITDA | $11.5M | — | -15.2% | — | — | |
| Net Income | -$4.6M | -7337.7% | — | — | -64.7% | |
| EPS (Diluted) | $-0.06 | -7361.2% | — | — | -64.1% | |
| Free Cash Flow | -$5.0M | -224.4% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 39.6% | 54.6% | 57.5% | 60.2% |
| Operating Margin | 5.8% | 4.4% | 8.3% | 8.1% |
| Net Margin | -30.1% | -9.2% | -1.0% | 2.5% |
| FCF Margin | -0.6% | 1.5% | 7.1% | 7.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.41 | $0.54 | +31.7% | ||
| Q1'26 | $0.79 | $0.83 | +5.1% | ||
| Q4'25 | $0.43 | $0.54 | +25.6% | ||
| Q3'25 | $0.43 | $0.45 | +4.7% | ||
| Q2'25 | $0.43 | $0.41 | -4.7% | ||
| Q1'25 | $0.86 | $0.97 | +12.8% | ||
| Q4'24 | $0.39 | $0.41 | +5.1% | ||
| Q3'24 | $0.62 | $0.63 | +1.6% |
Total return is +47.6% (1Y), outperforming the benchmark by +22.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +46.4% | +37.1% | — |
| 1Y | +47.6% | +22.6% | — |
| 3YCAGR | -24.4% | -44.5% | — |
| 5YCAGR | -23.9% | -36.8% | — |
| 10YCAGR | -7.4% | -21.2% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Integra LifeSciences Holdings Corporation (IART) valuation, health, and returns.
Integra LifeSciences Holdings Corporation is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +27.1% upside to DCF intrinsic value of $22.34)
Integra LifeSciences Holdings Corporation has multiple valuation anchors: DCF Intrinsic Value: $22.34 | Peer Relative Fair Value: $44.27 | Wall Street Analyst Target: $18.50 (implying +5.2% upside). A convergence of these signals offers higher conviction.
Integra LifeSciences Holdings Corporation displays weak financial health with a composite quality score of 26/100, supported by a Altman Z-Score of 0.5 (distress zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 1.7%.
Integra LifeSciences Holdings Corporation does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Integra LifeSciences Holdings Corporation's current growth trajectory is Stable. The company achieved +1.5% 1Y revenue growth and -7361.2% 1Y EPS growth, compared to its 3Y revenue CAGR of +1.6%.
Wall Street consensus is Buy based on 26 analysts, beating EPS expectations in 67% of recent quarters with a 4-quarter streak. The consensus price target represents a +5.2% change from current levels.
Investment risks for Integra LifeSciences Holdings Corporation include: -44.8% 1-year max drawdown, high beta (2.10x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 2.10x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.